Want to see CLRB full AI Analyst Report?
CLRB Stock Chart & Stats
$2.54
$0.02(0.79%)
At close: 4:00 PM EDT
$2.54
$0.02(0.79%)
Day’s Range― - ―
52-Week Range$2.20 - $6.52
Previous CloseN/A
Volume9.26K
Average Volume (3M)36.02K
Market Cap
$23.25M
Enterprise Value$1.54
Total Cash (Recent Filing)$33.99M
Total Debt (Recent Filing)$1.53M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Oct 29, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding9,452,108
10 Day Avg. Volume26,659
30 Day Avg. Volume36,016
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.67Price Target Upside359.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical ResponseHigh response rates and durable remission signals in heavily pretreated patients support iopofosine’s potential differentiation in Waldenstrom’s macroglobulinemia, strengthening the clinical rationale for continued development and future commercial adoption.
Defined Regulatory Development PathInitiating the confirmatory study and articulating a specific accelerated-approval pathway mark meaningful regulatory progress. Breakthrough status and a planned FDA review could shorten development timelines if enrollment and study execution remain on track.
Low Leverage And Improved Capital BaseMinimal debt limits fixed financial obligations and gives management greater flexibility to fund clinical programs. The rebuilt equity base improves solvency relative to prior periods, although continued losses mean capital preservation remains important.
Bears Say
Pre-Commercial Model And Persistent LossesCellectar remains entirely dependent on clinical and regulatory success because it has no commercial revenue base. Persistent losses provide limited visibility into future operating leverage and increase reliance on external financing until a product is approved.
Ongoing Cash Burn And Funding DependenceNegative cash generation means clinical development is not self-funding. The reliance on milestone-linked capital creates financing risk if execution slips, while continued research spending could shorten the effective runway before revenue or additional funding is available.
Clinical Execution And Supply-Chain ComplexityEnrollment and future commercialization depend on specialized sites, isotope logistics, and reliable radiopharmaceutical supply. Delays in approvals, site readiness, or isotope availability could postpone regulatory milestones and constrain the scalability of the pipeline.
Cellectar Biosciences News
CLRB FAQ
What was Cellectar Biosciences’s price range in the past 12 months?
Cellectar Biosciences lowest stock price was $2.20 and its highest was $6.52 in the past 12 months.
What is Cellectar Biosciences’s market cap?
Cellectar Biosciences’s market cap is $23.25M.
When is Cellectar Biosciences’s upcoming earnings report date?
Cellectar Biosciences’s upcoming earnings report date is Oct 29, 2026 which is in 55 days.
How were Cellectar Biosciences’s earnings last quarter?
Cellectar Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.05.
Is Cellectar Biosciences overvalued?
According to Wall Street analysts Cellectar Biosciences’s price is currently Undervalued.
Does Cellectar Biosciences pay dividends?
Cellectar Biosciences does not currently pay dividends.
What is Cellectar Biosciences’s EPS estimate?
Cellectar Biosciences’s EPS estimate is -0.56.
How many shares outstanding does Cellectar Biosciences have?
Cellectar Biosciences has 9,452,108 shares outstanding.
What happened to Cellectar Biosciences’s price movement after its last earnings report?
Cellectar Biosciences reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Cellectar Biosciences?
Currently, no hedge funds are holding shares in CLRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectar Biosciences
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
CLRB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.View all CLRB earnings summariesCLRB Stock 12 Month Forecast
Average Price Target
$11.67
▲(359.32% Upside)
Technical Analysis
Ownership Overview
0.97% Insiders
1.16% Mutual Funds
23.18% Other Institutional Investors
71.22% Public Companies and
Individual Investors